Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Trial ID or NCT#

NCT00725387

Status

not recruiting iconNOT RECRUITING

Purpose

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

Official Title

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patients older than 18-year-old, diagnosed with cancer - Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them
Exclusion Criteria:
  1. - Patients who cannot complete a PET/CT scan - Pregnant women - Healthy volunteers - Patients participating in other research studies The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.
View All Criteria
Show Less

Investigator(s)

Andrei Iagaru
Andrei Iagaru
Radiologist
Professor of Radiology (Nuclear Medicine)
Sanjiv Sam Gambhir, MD, PhD

Contact us to find out if this trial is right for you.

Contact

Andrei Iagaru
650-736-2859

View on ClinicalTrials.gov